Feature

Patient feedback can help ensure balance between cancer treatment efficacy, tolerability

March 18, 2019
Researchers have launched a research consortium that they hope will identify efficient methods to incorporate patient-reported outcomes into clinical…

NCI scientist to receive Szent-Györgyi Prize for Progress in Cancer Research

March 14, 2019
Steven A. Rosenberg, MD, PhD, will receive the 2019 Szent-Györgyi Prize for Progress in Cancer Research. The annual prize, awarded by National…
FDA News

FDA approves Tecentriq combination for PD-L1-positive, triple-negative breast cancer

March 8, 2019
The FDA granted
FDA News

FDA grants breakthrough therapy designation to Venclexta-Gazyva combination for untreated chronic lymphocytic leukemia

March 7, 2019
The FDA granted breakthrough therapy designation to venetoclax in combination with obinutuzumab as a fixed-duration, first-line regimen for…
Feature

Group to study immunotherapy-targeted therapy combination for metastatic colon cancer

March 7, 2019
Researchers at University of Colorado Cancer Center and partnering institutions received a grant to study a novel combination therapy for patients…
In the Journals

Pembrolizumab shows durable survival benefit in advanced non-small cell lung cancer

March 7, 2019
Pembrolizumab monotherapy continued to show a survival advantage over chemotherapy among certain patients with previously untreated, advanced…
Meeting News

HemOnc Today New York uses ‘practical, interactive approach’ to help providers improve cancer care

March 6, 2019
HemOnc Today is pleased to announce plans for a 3-day CME meeting designed to offer expert perspectives on advances in cancer treatment. …
Meeting NewsPerspective

Diet, supplements may affect immunotherapy response among patients with melanoma

February 28, 2019
Patients with melanoma who consumed high-fiber diets appeared to have better responses to anti-PD-1 immunotherapy than those who ate less fiber…
Meeting NewsPerspective

Pembrolizumab plus olaparib safe, active in docetaxel-pretreated men with prostate cancer

February 28, 2019
SAN FRANCISCO — The combination of pembrolizumab and olaparib demonstrated activity in men with metastatic castration-resistant prostate cancer…
In the Journals

Hematological adverse events with PD-1, PD-L1 inhibitors warrant better management

February 27, 2019
Hematological immune-related adverse events associated with PD-1 or PD-L1 inhibitors, such as neutropenia and hemolytic anemia, are rare but…